SureTrader Advertisement SureTrader
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

RCHA RSS Feed
Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, sunspotter, bearspread
Search This Board:
Last Post: 4/30/2016 8:49:07 AM - Followers: 190 - Board type: Free - Posts Today: 0




http://www.richpharmaceuticals.com/ 
 
 


http://www.otcmarkets.com/stock/RCHA/profile

 
RCHA Patent for Treatment of Hodgkin’s Lymphoma

http://www.richpharmaceuticals.com/wp-content/uploads/2014/10/Rich-10_13_14-HL-Patent-Ownership-Rights.pdf

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
 
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,


http://www.prnewswire.com/news-releases/rich-pharmaceuticals-announces-additional-submission-to-the-us-food-and-drug-administration-fda-300183133.html

http://finance.yahoo.com/news/rich-pharmaceuticals-announces-completion-manufacture-144500701.html

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

 
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
 
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
 
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
 
About Rich Pharmaceuticals:
 
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at www.richpharmaceuticals.com
 
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

http://finance.yahoo.com/q/ks?s=WX+Key+Statistics
http://finance.yahoo.com/q?s=wx&ql=1
http://www.wuxiapptec.com/


 
Below is the indicated Product Pipeline for RCHA:
Quote:


http://www.richpharmaceuticals.com/science-and-technology/pipeline/


Here is a key piece from the news as to how it applies:
Quote:


http://finance.yahoo.com/news/rich-pharmaceuticals-announces-completion-manufacture-144500701.html
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."


Courtesy of Sibware: 
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110569310 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.
 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 

AML 

It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.
 



RCHA Key DD Posts:
 
Key RCHA & WX:NYSE Relationship
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110555124
 
Respectfully, again, key with the Authorized Shares
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110551465
 

 
RCHA NEWS
 
http://finance.yahoo.com/q/h?s=RCHA+Headlines
http://www.richpharmaceuticals.com/category/news/
 

 
RCHA SEC FILINGS
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001504389&owner=exclude&count=40
 

 
http://www.richpharmaceuticals.com/contact-us/

Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003

E: info@richpharmaceuticals.com
 

 

 

Monthly View

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RCHA
Current Price
Volume:
Bid Ask Day's Range
Wiki
SureTrader
PostSubject
#11359  Sticky Note This is a Share Printing Scam Stock... AVOID makinezmoney 03/11/16 02:37:25 PM
#10158  Sticky Note When people discuss likely biopharma penny stock scams sunspotter 01/04/16 10:38:19 AM
#11525   That's what Ben chang is known for, the stanace27 04/30/16 08:49:07 AM
#11524   I agree. I can't post at all so Revorising 04/29/16 03:27:00 PM
#11523   I can't post more then 1 on the stockcrasher01 04/29/16 03:15:17 PM
#11522   Chinese Share Selling Scam. onthegreen 04/28/16 04:47:30 PM
#11521   Right so u can call others out and stockcrasher01 04/28/16 11:34:04 AM
#11520   Get a life bro. Revorising 04/28/16 11:25:52 AM
#11519   Right. So I'm a troll because I came stockcrasher01 04/28/16 11:22:45 AM
#11518   lol spoken like a troll who has nothing Revorising 04/28/16 11:13:31 AM
#11517   I find it amazing ull call a stock stockcrasher01 04/28/16 11:10:30 AM
#11516   Maybe he'll RS and repeat scam. Let's wait Slydogg27 04/27/16 06:53:37 PM
#11515   Wow what an utter piece of trash this is. Revorising 04/26/16 03:29:27 PM
#11514   Buy at .0001 in a month or so. Axeman 04/19/16 12:44:20 AM
#11513   Grabbing some opportunity while waiting for the next round. CashCassone 04/19/16 12:30:49 AM
#11512   253 billion OS now with newest 8k. Ben Axeman 04/19/16 12:27:08 AM
#11511   This has been exactly as you said it Drugdoctor 04/18/16 09:31:47 PM
#11510   LMFAO! ANOTHER 8K! BEN'S CONVERTING @ .0001 TO onthegreen 04/18/16 07:10:23 PM
#11509   Let’s see if lightning strikes again! BitCapitals 04/17/16 10:23:16 PM
#11508   yep like three of them vhgier 04/17/16 10:03:59 PM
#11507   Lmao! Ben keeps dumping!! onthegreen 04/14/16 10:36:05 PM
#11506   Ya just got it, A/S increase to 4B traderpie 04/14/16 07:21:52 PM
#11505   It says it increases from 375,030,000 shares to Rich Beachgal 04/14/16 05:18:38 PM
#11504   Anyone receive Sch14c in mail? Rich Beachgal 04/14/16 05:16:08 PM
#11503   I agree. I would do the same to Axeman 04/13/16 12:46:04 PM
#11502   Looks like 10k trades are in order, usual stoprun 04/13/16 12:45:05 PM
#11501   He's doing what he needs to do...nothing more vhgier 04/13/16 12:05:28 PM
#11500   You know what is going on with the Axeman 04/13/16 11:59:27 AM
#11499   Looks like, is it Ben, moving some shares vhgier 04/13/16 08:50:36 AM
#11498   Good day.... vhgier 04/12/16 08:59:12 PM
#11497   RCHA has the potential to bounce real hard Rich540 04/12/16 07:29:23 PM
#11496   News could be coming and hopefully it will Axeman 04/12/16 06:02:02 PM
#11495   What caused the 100% gain today? News coming?? Rich540 04/12/16 04:40:33 PM
#11494   Agreed vhgier 04/12/16 04:13:38 PM
#11493   Let's see if It can hold its gains Axeman 04/12/16 04:13:07 PM
#11492   let's just have fun boys and girls. vhgier 04/12/16 04:11:33 PM
#11491   Is that all you have to say on badshah 04/12/16 03:54:07 PM
#11490   Daily Dilution from Toxic notes. Axeman 04/12/16 11:23:35 AM
#11489   what's the verdict over here? Peckfito 04/12/16 04:33:12 AM
#11486   Like a said better here then the slots. vhgier 04/11/16 04:37:23 PM
#11485   Actually bad move since this is going no Axeman 04/11/16 04:18:01 PM
#11484   Just loaded up one more time. Better vhgier 04/11/16 04:00:17 PM
#11483   .0001 Not a safe bet either. Ben has onthegreen 04/11/16 02:16:31 PM
#11482   Wow! "Big Spender", 1500 shares @.0003= .45 cents stoprun 04/11/16 10:53:32 AM
#11481   .0001 again!!! In less than a month!! From Pstats 04/11/16 10:51:15 AM
#11480   Another 8k on the way! Dilution Machine onthegreen 04/06/16 08:14:43 PM
#11479   I have one pink that has a 12 kid biscuit 04/06/16 03:01:59 PM
#11477   Rich Pharmaceuticals Retains Contract Research Organization bearspread 04/05/16 02:03:42 PM
#11476   definitely a Rookie move on his part since he Axeman 04/05/16 01:07:38 AM
#11475   Only Buy at .0001. Ben has 100's of Axeman 04/05/16 01:04:56 AM
#11473   That's exactly what happened about a couple of Ortiz 04/04/16 11:20:52 PM
#11472   Why do you say that??? Rich540 04/04/16 11:14:34 PM
PostSubject